Zhang Fanrong, Ying Lisha, Jin Jiaoyue, Chen Kaiyan, Zhang Nan, Wu Junzhou, Zhang Yimin, Su Dan
Department of Oncology, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, China.
Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
Oncotarget. 2017 Jan 31;8(5):8835-8842. doi: 10.18632/oncotarget.13053.
To investigate the association between C-reactive protein/albumin ratio (CAR), an inflammation-based prognostic score, and clinicopathological factors, as well as its association with long-term outcomes in patients with operable non-small cell lung cancer (NSCLC).
A total of 617 operable NSCLC patients were retrospectively evaluated and the data of preoperative serum CRP and serum albumin was collected. The correlation between the CAR and clinicopathological factors was analyzed using the chi-square test. A Cox proportional hazards regression model was performed to evaluate the association between the CAR and outcome.
The CAR was significantly related to sex, smoking status, BMI, histology type and clinical stage (p ≤ 0.05). The patients with characteristic of male, smoker, BMI under 18.5, squamous cell carcinoma or clinical stage III had a high level of CAR. Additionally, elevated CAR indicated a worse outcome, and the patients with higher CAR had 2.02-fold risk for disease progression (95% CI 1.48-2.74, p < 0.001) and 2.61-fold risk for death (95 % CI 2.02-3.37, p < 0.001). Multivariate analyses showed the similar results after adjusted by clinicopathological factors and another four inflammation-based prognostic scores.
The CAR is a potential independent predictor for disease progression and death in patients with operable NSCLC.
探讨基于炎症的预后评分C反应蛋白/白蛋白比值(CAR)与临床病理因素之间的关联,以及其与可手术非小细胞肺癌(NSCLC)患者长期预后的关联。
回顾性评估617例可手术的NSCLC患者,收集术前血清CRP和血清白蛋白数据。采用卡方检验分析CAR与临床病理因素之间的相关性。采用Cox比例风险回归模型评估CAR与预后之间的关联。
CAR与性别、吸烟状态、BMI、组织学类型和临床分期显著相关(p≤0.05)。具有男性、吸烟者、BMI低于18.5、鳞状细胞癌或临床III期特征的患者CAR水平较高。此外,CAR升高提示预后较差,CAR较高的患者疾病进展风险为2.02倍(95%CI 1.48-2.74,p<0.001),死亡风险为2.61倍(95%CI 2.02-3.37,p<0.001)。多因素分析在经临床病理因素和另外四个基于炎症的预后评分调整后显示了相似的结果。
CAR是可手术NSCLC患者疾病进展和死亡的潜在独立预测因子。